Ariasi Cesare, Artelli Grazia Linda, Zane Cristina, Perantoni Martina, Soglia Simone, La Rosa Giuseppe, Maione Vincenzo, Venturini Marina, Zambelli Claudia, Licata Gaetano, Rossi Mariateresa, Arisi Mariachiara
Department of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.
Department of Pathology, University of Brescia, Brescia, Italy.
Dermatol Ther (Heidelb). 2025 May;15(5):1259-1273. doi: 10.1007/s13555-025-01363-9. Epub 2025 Feb 25.
Tumoral melanosis (TM) is a rare entity thought to result from the complete regression of melanoma. Clinically, TM resembles malignant melanocytic lesions, presenting as hyperpigmented flat or papulonodular lesions. Histologically, TM lacks melanocytes, instead showing inflammation, fibrosis, and melanophages. Diagnosing melanoma without melanocytes is challenging, and TM may also represent other regressed benign or malignant pigmented lesions. This study retrospectively analyzed 12 TM cases focusing on the clinical course, management, and potential for malignancy. Among the cases, 50% were associated with advanced or metastatic melanoma, supporting TM's potential as a regressed melanoma. Conversely, in 50% of cases, TM occurred without primary or metastatic melanoma, suggesting possible regression of a benign or malignant epithelial lesion such as pigmented basal cell carcinoma (BCC) or seborrheic keratosis (SK) or confinement of melanoma by the immune system. Management included surgical excision and follow-up similar to that of melanoma. Sentinel lymph node biopsy (SLNB) was selectively performed based on clinical suspicion and multidisciplinary team discussions. In conclusion, TM should be considered potentially regressed melanoma, especially in patients with high disease burden, and the possibility of derivation from high-grade melanomas must always be considered. Given the inability to distinguish TM from completely regressed melanoma, clinicians must remain vigilant and suspect this origin during staging and follow-up. Comprehensive management and close monitoring are crucial to address TM's clinical implications.
肿瘤性黑素沉着症(TM)是一种罕见的疾病,被认为是黑色素瘤完全消退的结果。在临床上,TM类似于恶性黑素细胞性病变,表现为色素沉着的扁平或丘疹结节性病变。在组织学上,TM缺乏黑素细胞,取而代之的是炎症、纤维化和噬黑素细胞。诊断没有黑素细胞的黑色素瘤具有挑战性,TM也可能代表其他消退的良性或恶性色素性病变。本研究回顾性分析了12例TM病例,重点关注其临床病程、治疗及恶变可能性。在这些病例中,50%与晚期或转移性黑色素瘤相关,支持TM作为消退性黑色素瘤的可能性。相反,在50%的病例中,TM发生时没有原发性或转移性黑色素瘤,提示可能是良性或恶性上皮性病变(如色素性基底细胞癌(BCC)或脂溢性角化病(SK))消退,或黑色素瘤被免疫系统局限。治疗包括手术切除及类似黑色素瘤的随访。根据临床怀疑和多学科团队讨论选择性地进行前哨淋巴结活检(SLNB)。总之,TM应被视为潜在消退的黑色素瘤,尤其是在疾病负担高的患者中,并且必须始终考虑其源自高级别黑色素瘤的可能性。鉴于无法将TM与完全消退的黑色素瘤区分开来,临床医生在分期和随访期间必须保持警惕并怀疑这种起源。综合治疗和密切监测对于应对TM的临床影响至关重要。